Linda Garland, MD
Dr. Linda Garland is a thoracic medical oncologist at the University of Arizona Banner Health. She has expertise in lung cancer and malignant pleural mesothelioma and is particularly interested in the use of experimental therapeutics to improve patient outcomes.[1]
Education and Career
Dr. Garland earned her medical degree at the University of Texas Health Science Center. She completed her internship and residency in Internal Medicine at the University of South Florida College of Medicine and a fellowship in Hematology and Oncology at the H. Lee Moffitt Cancer Center.
Upon completing her education and training, Dr. Garland served as Assistant Professor of Medicine in the Thoracic Oncology Program at H. Lee Moffitt Cancer Center in Tampa, Florida, and then accepted a position at the University of Arizona Cancer Center. In her role at the University of Arizona College of Medicine and Banner Health, she serves as director of Clinical Research in Thoracic Oncology and director of the Clinical Lung Cancer Program. She has previously served on the University of Arizona Institutional Review Board.[1]
Research
Dr. Garland is both a hands-on practitioner and a translational researcher. In her role as director of Clinical Research in Thoracic Oncology, she has designed investigator-initiated translational clinical trials with novel targeted agents in advanced lung cancer and malignant pleural mesothelioma and served as co-investigator and Principal Investigator on sequential NCI-funded lung cancer prevention trials. She also works collaboratively with other scientists in the preclinical development of novel cancer agents and imaging biomarkers and with biomedical engineers from the University of Arizona as a co-investigator for a randomized trial of a novel exercise intervention for cancer patients with peripheral neuropathy that provides evidence of improved balance outcomes relevant to fall prevention with the novel exercise intervention.[1]
Dr. Garland has co-authored over 34 peer-reviewed articles and participated in over 29 clinical trials in the past several years.
Her recent publications include:[1]
- Vrba L, Oshiro MM, Kim SS, Garland LL, Placencia C, Mahadevan D, Nelson MA, Futscher BW. 2020. DNA methylation biomarkers discovered detect cancer in liquid biopsies from non-small cell lung cancer patients. Epigenetics. 15:419–430. doi:10.1080/15592294.2019.1695333.
- Garland LL, Guillen-Rodriguez J, Hsu C-H, Yozwiak M, Zhang HH, Alberts DS, Davis LE, Szabo E, Merenstein C, Lel J, et al. 2019. Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial. Cancer Prev Res (Phila). 12:809–820. doi:10.1158/1940-6207.CAPR-19-0036.
- Eshghi N, Garland LL, Choudhary G, Hsu CC, Eshghi A, Han J, Hamilton RJ, Krupinski E, Kuo PH. 2018. Regional Changes in Brain F-FDG Uptake After Prophylactic Cranial Irradiation and Chemotherapy in Small Cell Lung Cancer May Reflect Functional Changes. J Nucl Med Technol. 46:355–358. doi:10.2967/jnmt.118.212316.
- Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 2018. F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. J Nucl Med Technol. 46:260–264. doi:10.2967/jnmt.117.204933.
- Centuori SM, Gomes CJ, Kim SS, Putnam CW, Larsen BT, Garland LL, Mount DW, Martinez JD. 2018. Double-negative (CD27IgD) B cells are expanded in NSCLC and inversely correlate with affinity-matured B cell populations. J Transl Med. 16:30. doi:10.1186/s12967-018-1404-z.
- Chow H-HS, Garland LL, Heckman-Stoddard BM, Hsu C-H, Butler VD, Cordova CA, Chew WM, Cornelison TL. 2014. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med. 12:223. doi:10.1186/s12967-014-0223-0.
- Chow H-HS, Garland LL, Hsu C-H, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 3:1168–75. doi:10.1158/1940-6207.CAPR-09-0155.
